New hope for advanced cancer: first human trial of ASD141 begins
NCT ID NCT06235437
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called ASD141 in 21 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the drug and be closely monitored for side effects and any signs of cancer control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cheng Kung University Hospital
RECRUITINGTainan, 704, Taiwan
Contact Phone: •••-•••-••••
Contact
-
Taipei Medical University Hospital
RECRUITINGTaipei, 110, Taiwan
Contact Phone: •••-•••-••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- Can a new nucleotide analogue boost cancer treatment?
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- Fighting cancer wasting: can diet and exercise make olanzapine work better?
- Can a new antibody help the immune system fight advanced cancers?
- Can an experimental pill slow advanced solid tumors? a phase 1 trial puts HW221043 to the test.